image
Healthcare - Biotechnology - NASDAQ - US
$ 2.04
-0.971 %
$ 56.1 M
Market Cap
-2.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one IMMX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.04 USD, Immix Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one IMMX stock under the base case scenario is HIDDEN Compared to the current market price of 2.04 USD, Immix Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one IMMX stock under the best case scenario is HIDDEN Compared to the current market price of 2.04 USD, Immix Biopharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
100.00%
-16.1 M OPERATING INCOME
-96.39%
-15.6 M NET INCOME
-89.50%
-11.4 M OPERATING CASH FLOW
-53.50%
-52.1 K INVESTING CASH FLOW
0.00%
15.5 M FINANCING CASH FLOW
378.44%
0 REVENUE
0.00%
-7.39 M OPERATING INCOME
-57.26%
-7.15 M NET INCOME
-62.75%
-4.04 M OPERATING CASH FLOW
23.21%
-272 K INVESTING CASH FLOW
-179.73%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Immix Biopharma, Inc.
image
Current Assets 19.8 M
Cash & Short-Term Investments 17.5 M
Receivables 1.17 M
Other Current Assets 1.11 M
Non-Current Assets 137 K
Long-Term Investments 0
PP&E 50.2 K
Other Non-Current Assets 87.2 K
Current Liabilities 3.72 M
Accounts Payable 1.43 M
Short-Term Debt 0
Other Current Liabilities 2.29 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Immix Biopharma, Inc.
image
Revenue 0
Cost Of Revenue 5.47 K
Gross Profit -5.47 K
Operating Expenses 16.1 M
Operating Income -16.1 M
Other Expenses -546 K
Net Income -15.6 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-94.03% ROE
-94.03%
-77.42% ROA
-77.42%
-98.56% ROIC
-98.56%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Immix Biopharma, Inc.
image
Net Income -15.6 M
Depreciation & Amortization 5.47 K
Capital Expenditures -52.1 K
Stock-Based Compensation 2.57 M
Change in Working Capital 1.65 M
Others -782 K
Free Cash Flow -11.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Immix Biopharma, Inc.
image
Wall Street analysts predict an average 1-year price target for IMMX of $7 , with forecasts ranging from a low of $7 to a high of $7 .
IMMX Lowest Price Target Wall Street Target
7 USD 243.14%
IMMX Average Price Target Wall Street Target
7 USD 243.14%
IMMX Highest Price Target Wall Street Target
7 USD 243.14%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Immix Biopharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
104 K USD 1
0-3 MONTHS
89.7 K USD 2
3-6 MONTHS
42.5 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 weeks ago
Dec 23, 2024
Bought 87.7 K USD
Hsu Jason
Director
+ 40000
2.192 USD
4 weeks ago
Dec 20, 2024
Bought 16.7 K USD
Hsu Jason
Director
+ 7700
2.166 USD
4 months ago
Aug 22, 2024
Bought 18.2 K USD
Hsu Jason
Director
+ 8100
2.251 USD
4 months ago
Aug 21, 2024
Bought 33.4 K USD
Hsu Jason
Director
+ 15000
2.226 USD
5 months ago
Aug 16, 2024
Bought 18.6 K USD
Ng Carey
Director
+ 10000
1.86 USD
5 months ago
Jul 24, 2024
Bought 12.9 K USD
Hsu Jason
Director
+ 6000
2.1462 USD
6 months ago
Jul 18, 2024
Bought 6.64 K USD
Hsu Jason
Director
+ 3200
2.0748 USD
7 months ago
Jun 07, 2024
Bought 5.54 K USD
Rachman Ilya M
CEO and Chairman
+ 2600
2.13 USD
7 months ago
Jun 07, 2024
Bought 5.3 K USD
Morris Gabriel S
CFO
+ 2500
2.1192 USD
7 months ago
Jun 04, 2024
Bought 5.97 K USD
Morris Gabriel S
CFO
+ 3300
1.8099 USD
7 months ago
Jun 04, 2024
Bought 5.97 K USD
Rachman Ilya M
CEO and Chairman
+ 3300
1.8091 USD
8 months ago
May 14, 2024
Bought 10 K USD
Morris Gabriel S
CFO
+ 4500
2.2315 USD
8 months ago
May 14, 2024
Bought 9.66 K USD
Rachman Ilya M
CEO and Chairman
+ 4300
2.2465 USD
1 year ago
Dec 11, 2023
Bought 145 K USD
Hsu Jason
Director
+ 31000
4.674 USD
1 year ago
Dec 08, 2023
Bought 122 K USD
Hsu Jason
Director
+ 25000
4.881 USD
1 year ago
Sep 15, 2023
Bought 17.4 K USD
Hsu Jason
Director
+ 7000
2.4852 USD
1 year ago
Sep 14, 2023
Bought 25.8 K USD
Hsu Jason
Director
+ 10000
2.5772 USD
1 year ago
Sep 12, 2023
Bought 84.9 K USD
Hsu Jason
Director
+ 30000
2.8288 USD
1 year ago
Sep 11, 2023
Bought 72.3 K USD
Hsu Jason
Director
+ 25000
2.8912 USD
1 year ago
Sep 14, 2023
Bought 25.8 K USD
Ng Carey
Director
+ 10000
2.576 USD
1 year ago
Sep 12, 2023
Bought 38.5 K USD
Adams Helen C.
Director
+ 13000
2.9609 USD
1 year ago
Sep 08, 2023
Bought 25.3 K USD
Hsu Jason
Director
+ 10000
2.5317 USD
1 year ago
Sep 07, 2023
Bought 49.2 K USD
BUCHAN MELISSA JANE
Director
+ 20000
2.4613 USD
1 year ago
Sep 06, 2023
Bought 22.2 K USD
Marquet Magda
Director
+ 9000
2.4681 USD
1 year ago
Sep 05, 2023
Bought 24.7 K USD
Marquet Magda
Director
+ 10000
2.4722 USD
1 year ago
Aug 31, 2023
Bought 2.01 K USD
Marquet Magda
Director
+ 1000
2.01 USD
2 years ago
Nov 14, 2022
Bought 148 USD
Rachman Ilya M
CEO and Chairman
+ 150
0.99 USD
2 years ago
Nov 14, 2022
Bought 950 USD
Rachman Ilya M
CEO and Chairman
+ 1000
0.95 USD
2 years ago
Nov 14, 2022
Bought 4.13 K USD
Rachman Ilya M
CEO and Chairman
+ 4050
1.019 USD
2 years ago
Nov 14, 2022
Bought 4.89 K USD
Morris Gabriel S
CFO
+ 5200
0.94 USD
2 years ago
Jul 14, 2022
Sell 550 USD
Senn Sean
- 200
2.75 USD
2 years ago
Jul 14, 2022
Sell 550 USD
Senn Sean
director:
- 200
2.75 USD
3 years ago
Dec 20, 2021
Bought 12.5 K USD
Rachman Ilya M
CEO and Chairman
+ 2500
5 USD
3 years ago
Dec 20, 2021
Bought 250 K USD
Hsu Jason
Director
+ 50000
5 USD
3 years ago
Dec 20, 2021
Bought 15 K USD
Torchilin Vladimir P
Scientific Co-Founder
+ 3000
5 USD
3 years ago
Dec 17, 2021
Bought 9.83 K USD
Torchilin Vladimir P
Scientific Co-Founder
+ 2200
4.47 USD
3 years ago
Dec 20, 2021
Bought 10 K USD
Morris Gabriel S
Chief Financial Officer
+ 2000
5 USD
3 years ago
Dec 20, 2021
Bought 125 K USD
Ng Carey
Director
+ 25000
5 USD
7. News
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow MRD negative (10-6); all patients remain in response as of the data cutoff of Nov 14, 2024 Bone marrow MRD negativity predicts future CR; company believes remaining two patients could be confirmed as CRs in the coming weeks and months Company to provide next program update in H1 2025 Conference call to discuss results Dec 19 at 11:00 a.m. ET (link to attend) LOS ANGELES, CA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced initial clinical data from the first four patients in the ongoing NEXICART-2 (NCT06097832) U.S. study of sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in relapsed/refractory AL Amyloidosis. globenewswire.com - 1 month ago
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients LOS ANGELES, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, announced today the Journal of Clinical Oncology (JCO) published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The data reported on 16 enrolled patients in NEXICART-1 who had received a median 4 prior lines of therapy prior to treatment with NXC-201. globenewswire.com - 1 month ago
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December 9, 2024 Best responder duration of response was 31.5 months with complete response ongoing as of December 9, 2024 Conference call to discuss results Tuesday, December 10, 2024 4:30 p.m. ET at https://zoom.us/j/94736340854?pwd=LTBtu2LuvwSb6S6ISuH5yKTDLsI2vt.1 LOS ANGELES, CA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that new NXC-201 NEXICART-1 clinical data in relapsed/refractory AL Amyloidosis has been presented at 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. globenewswire.com - 1 month ago
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media - Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management's formal remarks, there will be a question-and-answer session. globenewswire.com - 1 month ago
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients 75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that additional NEXICART-1 NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 7-10, 2024. “NXC-201 is the only CAR-T in development for relapsed/refractory AL amyloidosis patients,” said Ilya Rachman, MD PhD, Chief Executive Officer of Immix Biopharma. globenewswire.com - 1 month ago
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studies Lead site Memorial Sloan Kettering Cancer Center (MSKCC); 4 disclosed clinical sites so far NXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials AL Amyloidosis, a disorder of plasma cells that leads to progressive damage to the heart, kidney and liver, affects approximately 33,000 patients in the U.S. LOS ANGELES, CA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced advances in the NEXICART-2 clinical study of its CAR-T NXC-201 for relapsed/refractory AL Amyloidosis, a plasma cell disorder that leads to progressive damage to the heart, kidney and liver, which currently affects approximately 33,000 patients in the U.S. Immix Biopharma's sterically-optimized CAR-T NXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials. globenewswire.com - 3 months ago
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq: IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medical Center, joined ImmixBio subsidiary Nexcella Scientific Advisory Board. globenewswire.com - 4 months ago
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Data from ex-U.S. clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, CA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and immune-mediated diseases, today announced the addition of three additional clinical trial sites for its U.S. relapsed/refractory AL Amyloidosis clinical trial NEXICART-2. The newly added centers include some of the leading programs in the world in AL Amyloidosis. globenewswire.com - 4 months ago
What Makes Immix Biopharma (IMMX) a New Buy Stock Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 5 months ago
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis globenewswire.com - 5 months ago
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis globenewswire.com - 5 months ago
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy. globenewswire.com - 6 months ago
8. Profile Summary

Immix Biopharma, Inc. IMMX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 56.1 M
Dividend Yield 0.00%
Description Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Contact 11400 West Olympic Boulevard, Los Angeles, CA, 90064 https://www.immixbio.com
IPO Date Dec. 16, 2021
Employees 14
Officers Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. Scientific Co-Founder Mr. Nandan Oza B.S. Head of Chemistry, Manufacturing & Control Mr. Gerhard Bauer Head of Cell Therapy Manufacturing Dr. Graham Ross FFPM, M.D. Chief Medical Officer & Head of Clinical Development Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc Co-Founder Dr. David Marks Chief Medical Officer of Cell Therapy Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. Co-Founder, Chief Executive Officer & Chairman Mr. Gabriel Morris B.A. Chief Financial Officer & Director